|
|
| Line 1: |
Line 1: |
| − | ==Annotation== | + | ==Annotated Information== |
| − | ===Name=== | + | ===Name=== |
| − | [[File:High expression of linc00210 in liver cancer and liver TICs.jpg|right|thumb|High expression of linc00210 in liver cancer and liver TICs<ref name="ref2" />.]]
| + | Approved symbol： LINC02885 |
| − | Approved symbol: LINC00210 | + | |
| − | | + | Approved name： long intergenic non-protein coding RNA 2885 |
| − | Approved name: long intergenic non-protein coding RNA 210 | + | |
| − | | + | HGNC ID： HGNC:41188 |
| − | HGNC ID: HGNC:37458 | + | |
| − | | + | Previous symbols： ISX-AS1 |
| − | Previous symbols: NCRNA00210 | + | |
| − | | + | Previous names： ISX antisense RNA 1 |
| − | Previous names: non-protein coding RNA 210 | + | |
| − | | + | RefSeq ID： NR_138042 |
| − | Alias symbols: RP11-72L13.1
| |
| − | | |
| − | RefSeq ID: NR_048550 | |
| − | | |
| − | ===Characteristics ===
| |
| − | [[File:Linc00210 participated in Wnt β-catenin activation.jpg|right|thumb|Linc00210 participated in Wnt β-catenin activation<ref name="ref2" />.]]
| |
| − | | |
| − | ===Expression===
| |
| − | NCRNA00210 increased in A549/CDDP (all P <0.05)<ref name="ref1" />.
| |
| − | | |
| − | Highly expressed in liver cancer and liver TICs<ref name="ref2" />.
| |
| − | | |
| − | ===Regulation===
| |
| − | Please input regulation information here.
| |
| − | | |
| − | ===Function===
| |
| − | Linc00210 drives the self-renewal and propagation of liver TICs through activating Wnt/β-catenin signaling. Linc00210 interacts with CTNNBIP1 and blocks the combination between CTNNBIP1 and β-catenin, driving the activation of Wnt/β-catenin signaling. Linc00210-CTNNBIP1-Wnt/β-catenin axis can be targeted for liver TIC elimination<ref name="ref2" />.
| |
| − | | |
| − | ===Disease===
| |
| − | non-small cell lung cancer <ref name="ref1" />
| |
| − | | |
| − | liver cancer<ref name="ref2" />
| |
| − | | |
| − | liver TICs<ref name="ref2" />
| |
| − | | |
| − | ===Evolution===
| |
| − | Please input evolution information here.
| |
| − | | |
| − | ==Labs working on this lncRNA==
| |
| − | * Beijing Key Laboratory of Respiratory and Pulmonary Circulation, Capital Medical University, Beijing, China.
| |
| − | * Department of Cancer Biology Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 127 Dongming Road, Zhengzhou, Henan, 450003, China.
| |
| − | * Department of Histology and Embryology, College of Basic Medicine, Zhengzhou University, 100 Kexue Road, Zhengzhou, Henan, 450052, China.
| |
| − | | |
| − | ==References==
| |
| − | <references>
| |
| − | <ref name="ref1"> Yang Y, Li H, Hou S, et al. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell[J]. PLoS One, 2013, 8: e65309.
| |
| − | </ref>(1)
| |
| − | | |
| − | <ref name="ref2">Fu X, Zhu X, Qin F, et al. Linc00210 drives Wnt/beta-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner[J]. Mol Cancer, 2018, 17: 73.</ref>(2)
| |
| − | | |
| − | </references>
| |
